- Home
- AARD vs CBIO Comparison
AARD vs CBIO Comparison
Compare AARD & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- CBIO
- Stock Information
- Founded
- AARD 2017
- CBIO 2003
- Country
- AARD United States
- CBIO United States
- Employees
- AARD N/A
- CBIO N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- CBIO
- Sector
- AARD Health Care
- CBIO
- Exchange
- AARD Nasdaq
- CBIO Nasdaq
- Market Cap
- AARD 231.9M
- CBIO 208.8M
- IPO Year
- AARD 2025
- CBIO N/A
- Fundamental
- Price
- AARD $9.91
- CBIO $13.00
- Analyst Decision
- AARD Strong Buy
- CBIO Strong Buy
- Analyst Count
- AARD 8
- CBIO 5
- Target Price
- AARD $30.63
- CBIO $25.60
- AVG Volume (30 Days)
- AARD 162.6K
- CBIO 66.5K
- Earning Date
- AARD 11-13-2025
- CBIO 11-06-2025
- Dividend Yield
- AARD N/A
- CBIO N/A
- EPS Growth
- AARD N/A
- CBIO N/A
- EPS
- AARD N/A
- CBIO N/A
- Revenue
- AARD N/A
- CBIO N/A
- Revenue This Year
- AARD N/A
- CBIO N/A
- Revenue Next Year
- AARD N/A
- CBIO N/A
- P/E Ratio
- AARD N/A
- CBIO N/A
- Revenue Growth
- AARD N/A
- CBIO N/A
- 52 Week Low
- AARD $4.88
- CBIO $9.81
- 52 Week High
- AARD $19.58
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- AARD 39.27
- CBIO 55.93
- Support Level
- AARD $9.34
- CBIO $12.68
- Resistance Level
- AARD $11.51
- CBIO $13.45
- Average True Range (ATR)
- AARD 0.85
- CBIO 0.52
- MACD
- AARD -0.01
- CBIO 0.05
- Stochastic Oscillator
- AARD 20.39
- CBIO 70.69
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.